DelistingJun 24, 2026, 11:46 AM
Aditxt Delisted from Nasdaq; Trading Suspended June 25
AI Summary
Aditxt, Inc. announced that the Nasdaq Hearings Panel has denied its request to continue listing on The Nasdaq Stock Market. As a result, trading in the company's common stock will be suspended at the open of trading on June 25, 2026. The delisting stems from the company's failure to comply with Nasdaq's minimum bid price rule and minimum stockholders' equity requirement, with a reported negative stockholders' equity of $35,174,386. The Panel cited concerns over the company's compliance plan, including skepticism about the valuation of a subsidiary and the lack of revenue-generating products from its remaining operations.
Key Highlights
- Nasdaq Hearings Panel denied Aditxt's request to continue listing.
- Trading in Aditxt's common stock will be suspended at the open of trading on June 25, 2026.
- Company violated Nasdaq's Bid Price Rule (below $1.00) and Stockholders' Equity Rule (negative $35,174,386).
- Aditxt was not eligible for a compliance period due to multiple reverse stock splits over the prior two years.
- Panel expressed skepticism regarding the $150 million valuation of subsidiary Ignite Proteomics.
- Remaining subsidiaries have no revenue-generating drugs or devices, with quarterly losses of approximately $5 million.
- Aditxt has completed seven reverse stock splits to date, including one in May 2026.
- Company may request a review of the Panel's decision by the Nasdaq Listing and Hearing Review Council within 15 days.
Price Impact
More from ADTX